CD40 antibodies have been shown in preclinical studies to improve responses to combinations of chemotherapy or radiotherapy with anti-PD1 and anti-CTLA4 in pancreatic cancer, one of the tumors most resistant to immunotherapy64,65. Here, PDCD1 is linked to familial pancreatic carcinoma.